A short peptide from Vladimir Khavinson’s bioregulator programme directed at prostate tissue, related to the earlier extract Prostatilen.

Why does the prostate attract this kind of research?

Because it is one of the few organs that continues enlarging throughout adult life, typically resuming growth from around the fourth decade. Since it surrounds the urethra, that continued growth has practical consequences, and research focus falls on regulation rather than repair.

How does Prostamax differ from Prostatilen?

Prostatilen is a first-generation peptide extract with Russian registration and the longer clinical record. Prostamax is a synthesised short peptide from the same research line with a smaller published base.

How strong is the evidence?

Limited — largely preclinical and from the originating institute, with no approval from the TGA, FDA or EMA.

Why does the prostate keep growing?

Continued enlargement throughout adult life is the organ's normal pattern rather than a malfunction — it is one of very few organs that behaves this way. It is also strongly hormone-responsive, which is unusual for tissue still actively growing in later life.

Why does that growth cause problems?

Because of position rather than the growth itself. The prostate surrounds the urethra, so enlargement presses on the tube passing through it. The same growth in a differently placed organ would go unnoticed. It is a plumbing arrangement rather than a pathology.

Research Library›Bioregulators & Neuropeptides›Prostamax

Prostate Bioregulator

Prostamax: The Prostate Peptide and an Organ That Keeps Growing

A short peptide aimed at prostate tissue — one of the few organs that continues enlarging throughout adult life.

5 min read·4 studies cited·Updated July 2026

Evidence level

Preclinical only — animal and cell studies

What this level means

Quick Reference

Type	Short peptide
Target tissue	Prostate
Related compound	Prostatilen (extract)
Generation	Synthetic

What Is Prostamax?

Prostamax is a short peptide from the Khavinson family directed at prostate tissue. It sits alongside Prostatilen, the first-generation extract from the same research line and one of the six peptide preparations introduced into Soviet medical practice.

An organ that does not know when to stop, in plain language: most organs reach adult size and stay there. The prostate does not. It grows through puberty, pauses, then from around the fourth decade begins enlarging again and generally keeps going for the rest of a man’s life. Since it sits wrapped around the urethra, this is rather like a tree slowly thickening around a garden hose. Nothing is diseased in the ordinary sense — the growth is simply continuing long after its purpose has passed, which is why prostate research is unusually focused on regulation rather than repair.

What the Research Examines

Published work examines prostate tissue function and cellular markers in animal models. Prostatilen, the extract counterpart, holds Russian registration and has the longer clinical record of the two; Prostamax as a synthesised peptide has a smaller published base.

As with the rest of the synthesised family, evidence originates chiefly from the developing institute, independent replication is limited, and there is no approval from the TGA, FDA or EMA.

The Organ That Never Stops Growing

Most organs reach adult size and stay there. The prostate does not. It is one of very few that continues enlarging throughout adult life, and that single behaviour is why it attracts so much research attention.

Growth is not a malfunction here — it is the organ's normal pattern. Picture a tree growing in a courtyard slightly too small for it. The tree is not diseased and it is doing exactly what trees do. The difficulty is entirely about where it is: the prostate surrounds the urethra, so enlargement presses on the tube passing through it.

Position is the whole problem. The same growth in a differently placed organ would go unnoticed for a lifetime. It is a plumbing arrangement, not a pathology, and it is why enlargement becomes noticeable so commonly with age.

The tissue is also strongly hormone-responsive, which is unusual for an organ still actively growing in later life, and it is the reason the prostate features so heavily in endocrine research.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed